6 results about "Systemic absorption" patented technology

The present invention relates to oral films containing an active pharmaceutical ingredient (API) capable of providing seizure relief and one or more film-forming polymers, the use of such films, for example for the acute treatment of ongoing seizures, and methods for preparing such films. The film according to the invention is characterized by a rapid dissolution in the buccal cavity followed by a rapid and high systemic absorption.

A transdermal patch for delivering lidocaine for pain relief comprises a backing layer, an adhesive layer, and a composition containing lidocaine in an amount ranging from about 1% to about 10% by weight and heparin as a non-anticoagulant permeation enhancer in an amount ranging from about 1% to about 50% by weight. The heparin enhances permeation of lidocaine through the skin without exerting systemic anticoagulant effects by temporarily disrupting lipid bilayers in the stratum corneum to create microchannels for increased diffusion of lidocaine molecules. The patch provides effective relief for multiple pain types including neuropathic pain, inflammatory pain, ischemic pain, post-surgical pain, nociplastic pain, mechanical pain, and compressive pain. The transdermal patch is configured to provide sustained release of lidocaine for periods ranging from about 8 hours to about 24 hours, reducing pain by at least 50% with minimal systemic absorption.

This invention provides a topical finasteride formulation and its preparation method, belonging to the field of pharmaceutical formulation technology. The topical finasteride formulation provided by this invention is a topical dosage form, comprising finasteride and excipients; after scalp administration, the concentration in hair follicles and the epidermis is 999-5021 pg / mL, and the systemic blood concentration is 17.1-178.9 pg / mL; the systemic blood concentration is 1-10% of that of oral finasteride formulations. The method involves preparing finasteride and excipients, followed by steps of dissolving / preparing the matrix, fine filtration / homogenization, and filling to obtain finasteride topical formulations of different dosage forms. This invention effectively solves the shortcomings of existing finasteride formulations, such as high systemic absorption, high risk of adverse reactions, and difficulty in industrializing the process, making it suitable for large-scale clinical application in androgenetic alopecia, combining efficacy and safety.

The invention relates to formulation for oral delivery of peptides and / or drug molecules and a method of manufacturing the same. The oral formulation is useful for delivering peptides to the gastrointestinal tract, preferably at the ileo-caecal junction of colon.

The invention discloses a hyoscyamine derivative and a preparation method thereof, relates to the field of drug synthesis, and aims to provide an effective and safe drug molecule for inhalation / local pulmonary administration. According to the invention, a linear polyethylene glycol chain containing seven ethylene glycol repeating units is introduced into a hydroxyl site of hyoscyamine, and quaternization is carried out on a nitrogen atom of the hyoscyamine, so that the hyoscyamine derivative is prepared. The derivative is specially designed for inhalation / local lung drug delivery, through structural modification, systemic absorption and central penetration of the compound are reduced, local exposure of the lung is improved, residence time in the lung is prolonged, and meanwhile good atomization performance is taken into account.

This invention discloses a hyoscyamine derivative and its preparation method, relating to the field of drug synthesis, and aims to provide an effective and safe drug molecule for inhalation / local pulmonary administration. The invention prepares the hyoscyamine derivative by introducing a linear polyethylene glycol chain containing seven ethylene glycol repeating units at the hydroxyl position of hyoscyamine and quaternizing its nitrogen atom. This derivative is specifically designed for inhalation / local pulmonary administration. Through the above structural modification, it achieves reduced systemic absorption and central penetration of the compound, increased local lung exposure, and prolonged pulmonary retention time, while also maintaining good nebulization performance.